BridgeBio Pharma, Inc. — Director's Dealing 2026

Feb 19, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2026-02-16

Reporting Person: Apuli Maricel (Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-16	Common Stock	F	4349	$75.25	Disposed	124455	Direct
2026-02-17	Common Stock	S	510	$74.31	Disposed	123945	Direct

Footnotes

F1: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 8,377 shares of Common Stock underlying the Reporting Person's RSUs.

F2: Includes 510 shares of the Issuer's Common Stock acquired by the Reporting Person on February 13, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.